A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 156 participants.
Also called NCT07421232
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 156 participants
- Registry
-
NCT07421232
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT07421232. Randomized; single masking; primary purpose treatment. Start 2024-12-03 (actual); primary completion 2025-08-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
- Condition
- Hypercholesterolemia and Mixed Hyperlipidemia
- Intervention (Drug)
- SYH2053/placebo injection
- Intervention (Drug)
- Inclisiran (Leqvio®) 300mg
- Lead sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Record details
- Record id
cardio:ct-nct07421232- Content hash
8e8db29e8bf35f30aa10843a1b4c33b9230f552e33e695b7593766555bbffe32